MD Anderson's Phase 2 Trial Shows Success of Lorazepam and Haloperidol Combination Therapy for Managing Delirium in Patients with Advanced Cancer
Background and Objectives of the Phase 2 Clinical Trial
Agitated delirium, a common occurrence in patients with advanced cancer nearing the end of life, is a debilitating symptom that causes significant distress for both patients and their caregivers. Researchers at The University of Texas MD Anderson Cancer Center conducted a Phase 2 trial (NCT01949662) to evaluate the clinical efficacy of a combination therapy involving the addition of lorazepam, a benzodiazepine, to haloperidol, a standard antipsychotic medication, for the effective management of this condition. While the administration of benzodiazepines to patients with delirium has historically been avoided due to concerns about potentially exacerbating cognitive impairment, this study focused on exploring the value of proportional sedation as a novel therapeutic approach within the context of palliative care for terminally ill patients.
Key Results and Data Analysis of the Clinical Trial
A total of 111 patients were enrolled in the clinical trial, with 75 randomly assigned in a double-blind manner to receive either placebo, haloperidol alone, lorazepam alone, or a combination of haloperidol and lorazepam intravenously (IV) every four hours. The results showed that the treatment groups including lorazepam demonstrated significant symptom relief, as analyzed using the Richmond Agitation-Sedation Scale-Palliative Version (RASS-PAL) over a 24-hour period. Specifically, the proportion of patients requiring rescue medication for additional anxiety control was 32% in the combination therapy group and 37% in the lorazepam alone group, compared to 56% in the haloperidol alone group and 83% in the placebo group, representing a statistically significant difference (P=0.006) and confirming the clinical superiority of the combination therapy.
Impact on the Palliative Care Market and Industry
The findings of this study, published in the prestigious journal JAMA Oncology in September 2025, have garnered significant attention from both the academic and industry communities. The study demonstrated that lorazepam, which had previously been a concern for potentially worsening delirium, can be a safe and effective tool for suppressing agitation in terminally ill cancer patients, thereby challenging conventional wisdom. This is particularly significant in the context of the global palliative care market, which is estimated to be worth approximately $27 billion (approximately 36 trillion Korean Won), as it provides a cost-effective and efficient standard of care by repurposing existing, low-cost, off-patent drugs instead of developing expensive new drugs.
Standardization of Clinical Protocols and Future Prospects
Although this trial was a small, multi-center study, it is expected to contribute to the standardization of proportional sedation protocols in the field of palliative care by successfully completing a rigorous, randomized controlled trial (RCT). Despite challenges such as a slower-than-expected patient enrollment rate due to the COVID-19 pandemic, the researchers applied a repeated measures mixed model to achieve statistical significance using data from only 72 patients, further enhancing the reliability of the final results. As a result, it is likely that lorazepam IV administration will be officially recommended in palliative care guidelines in the future, which will be a significant step forward in helping terminally ill cancer patients maintain their dignity and reducing unnecessary healthcare resource utilization.
The completion and publication of this Phase 2 trial marks a turning point in the approximately $27 billion annual palliative care services market, triggering a shift in guidelines for managing the previously unmet need of delirium in terminally ill patients. Researchers and healthcare professionals are likely to adopt proportional sedation as a standard treatment protocol, given the significant improvement observed in rescue medication requirements, from 83% with haloperidol alone to 32% (P=0.006) with the addition of lorazepam. From an investor perspective, this study highlights the potential for repurposing low-cost, generic drugs (haloperidol and lorazepam) to achieve high efficiency in Phase 2 trials, paving the way for a cost-effective commercialization strategy. In the long term, palliative care centers and nursing facilities can leverage this clinical data to improve patient care efficiency and reduce unnecessary transfers to intensive care units, leading to significant cost savings. This study also lays the groundwork for future large-scale Phase 3 confirmatory trials to further validate these findings, establish a comparative advantage over competing pipeline products targeting similar indications (e.g., dexmedetomidine), and ultimately maximize the quality of life for patients in the terminal stages of their illness.
Source: ClinicalTrials.gov (api_ct)